SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

WFRF:(Wallentin Lars 1943 )
 

Search: WFRF:(Wallentin Lars 1943 ) > (2010-2014) > James Stefan K. 1964 > Angiolillo Dominick J. > Association of Prot...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor : Outcomes With Clopidogrel and Ticagrelor

Goodman, Shaun G. (author)
Clare, Robert (author)
Pieper, Karen S. (author)
show more...
Nicolau, Jose C. (author)
Storey, Robert F. (author)
Cantor, Warren J. (author)
Mahaffey, Kenneth W. (author)
Angiolillo, Dominick J. (author)
Husted, Steen (author)
Cannon, Christopher P. (author)
James, Stefan K, 1964- (author)
Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR),Kardiologi
Kilhamn, Jan (author)
Steg, P. Gabriel (author)
Harrington, Robert A. (author)
Wallentin, Lars, 1943- (author)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),kardiologi
show less...
 (creator_code:org_t)
2012
2012
English.
In: Circulation. - 0009-7322 .- 1524-4539. ; 125:8, s. 978-986
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background-The clinical significance of the interaction between clopidogrel and proton pump inhibitors (PPIs) remains unclear. Methods and Results-We examined the relationship between PPI use and 1-year cardiovascular events (cardiovascular death, myocardial infarction, or stroke) in patients with acute coronary syndrome randomized to clopidogrel or ticagrelor in a prespecified, nonrandomized subgroup analysis of the Platelet Inhibition and Patient Outcomes (PLATO) trial. The primary end point rates were higher for individuals on a PPI (n = 6539) compared with those not on a PPI (n = 12 060) at randomization in both the clopidogrel (13.0% versus 10.9%; adjusted hazard ratio [HR], 1.20; 95% confidence interval [CI], 1.04 -1.38) and ticagrelor (11.0% versus 9.2%; HR, 1.24; 95% CI, 1.07-1.45) groups. Patients on non-PPI gastrointestinal drugs had similar primary end point rates compared with those on a PPI (PPI versus non-PPI gastrointestinal treatment: clopidogrel, HR, 0.98; 95% CI, 0.79-1.23; ticagrelor, HR, 0.89; 95% CI, 0.73-1.10). In contrast, patients on no gastric therapy had a significantly lower primary end point rate (PPI versus no gastrointestinal treatment: clopidogrel, HR, 1.29; 95% CI, 1.12-1.49; ticagrelor, HR, 1.30; 95% CI, 1.14-1.49). Conclusions-The use of a PPI was independently associated with a higher rate of cardiovascular events in patients with acute coronary syndrome receiving clopidogrel. However, a similar association was observed between cardiovascular events and PPI use during ticagrelor treatment and with other non-PPI gastrointestinal treatment. Therefore, in the PLATO trial, the association between PPI use and adverse events may be due to confounding, with PPI use more of a marker for, than a cause of, higher rates of cardiovascular events.

Keyword

acute coronary syndrome
clopidogrel
mortality
myocardial infarction
ticagrelor

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view